Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iason gmbh - fluorometil-(18f)-dimetil-2-hidroksietil-amonij - raztopina za injiciranje - fluorometil-(18f)-dimetil-2-hidroksietil-amonij 1 gbq / 1 ml - (18f)fluoroholin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iason gmbh - fluorometil-(18f)-dimetil-2-hidroksietil-amonij - raztopina za injiciranje - fluorometil-(18f)-dimetil-2-hidroksietil-amonij 1 gbq / 1 ml - (18f)fluoroholin

Evropska unija - slovenščina - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - leiomyoma - hipofize in hipotalamični hormoni in analogi - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Evropska unija - slovenščina - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imunosupresivi - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - insulin aspart - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - acetilholin - prašek in vehikel za raztopino za intraokularno vkapavanje - acetilholin 20 mg / 1 mg - acetilholin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmacevtska oblika nedoločena - hranila brez fenilalanina

Evropska unija - slovenščina - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinurija, paroksizmal - imunosupresivi - soliris je navedeno pri odraslih in otrocih za zdravljenje:paroxysmal nočne haemoglobinuria (pnh). dokazila o kliničnih koristi je dokazana pri bolnikih z haemolysis z klinični simptom(i) okvirni visoke aktivnosti bolezni, ne glede na to, transfuzijo zgodovine (glej poglavje 5. netipične haemolytic uremic sindrom (ahus). soliris je navedeno pri odraslih za zdravljenje:ognjevzdržni splošnih myasthenia gravis (gmg) pri bolnikih, ki so anti-receptorjev acetilholina (achr) protitelesa-pozitivna (glej poglavje 5. neuromyelitis optica spectrum disorder (nmosd) pri bolnikih, ki so anti-aquaporin-4 (aqp4) protitelesa-pozitivno z recidivno potek bolezni.

Evropska unija - slovenščina - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - donepezil - orodisperzibilna tableta - donepezil 4,56 mg / 1 tableta - donepezil